Kim, Yungi

写真a

Affiliation

Faculty of Pharmacy 創薬研究センター (Shiba-Kyoritsu)

Position

Professor (Non-tenured)

Related Websites

Career 【 Display / hide

  • 2006.01
    -
    2011.07

    University of Michigan, Department of Pathology, Post-doctral fellow

  • 2011.07
    -
    2013.06

    筑波大学, 医学医療系, 助教

  • 2013.06
    -
    2015.06

    University of Michigan, Department of Pathology, Research Investigator

  • 2015.06
    -
    2016.07

    Vedanta Biosciences, Inc., Senior Scientist

  • 2016.08
    -
    2018.09

    慶應義塾大学, 薬学部生化学講座, 准教授

display all >>

Academic Degrees 【 Display / hide

  • 博士(薬学), 北里大学, 2005.03

Licenses and Qualifications 【 Display / hide

  • 薬剤師, 2000

 

Research Keywords 【 Display / hide

  • アレルギー

  • 感染免疫

  • 腸内細菌

  • 自然免疫

Research Themes 【 Display / hide

  • 腸内環境調節と炎症性疾患の制御に関する研究, 

    2016
    -
    Present

 

Books 【 Display / hide

  • ヒトマイクロバイオーム Vol.2 ~解析技術の進展とデータ駆動型・ターゲット機能型研究最前線~

    金 倫基,  (株)エヌティーエス, 2020.06

    Scope: 第2節 乳幼児の腸内細菌叢の特性

  • 腸内細菌叢を標的とした医薬品と保健機能食品の開発

    金 倫基, 技術情報協会, 2018.09

    Scope: 腸内細菌叢の創薬応用の研究開発の現状と可能性について

  • ヒトマイクロバイオーム研究最前線

    金 倫基渋谷 彰, (株)エヌ・ティー・エス, 2016.03

    Scope: 腸内細菌叢と喘息

Papers 【 Display / hide

  • Butyricimonas is a key gut microbiome component for predicting postoperative recurrence of esophageal cancer

    Otsuka K., Isobe J., Asai Y., Nakano T., Hattori K., Ariyoshi T., Yamashita T., Motegi K., Saito A., Kohmoto M., Hosonuma M., Kuramasu A., Baba Y., Murayama M, Narikawa Y., Toyoda H., Funayama E., Tajima K., Shida M., Hirasawa Y., Tsurui T, Ariizumi H., Ishiguro T., Suzuki R., Ohkuma R., Kubota Y., Sambe T., Tsuji M., Wada S., Kiuchi Y. , Kobayashi S., Horiike A., Goto S., Murakami M., Kim Y. G., Tsunoda T., Yoshimura K.

    Cancer Immunology, Immunotherapy Accepted 2023.12

    Research paper (scientific journal), Joint Work, Accepted

  • Amino acid catabolite markers for early prognostication of pneumonia in patients with COVID-19

    Maeda R., Seki N., Uwamino Y., Wakui M., Nakagama Y., Kido Y., Sasai M., Taira S., Toriu N., Yamamoto M., Matsuura Y., Uchiyama J., Yamaguchi G., Hirakawa M., Kim Y. G., Mishima M., Yanagita M., Suematsu M., Sugiura Y.

    Nature Communications (Nature Communications)  Accepted ( 1 )  2023.12

    Research paper (scientific journal), Joint Work, Accepted

     View Summary

    Effective early-stage markers for predicting which patients are at risk of developing SARS-CoV-2 infection have not been fully investigated. Here, we performed comprehensive serum metabolome analysis of a total of 83 patients from two cohorts to determine that the acceleration of amino acid catabolism within 5 days from disease onset correlated with future disease severity. Increased levels of de-aminated amino acid catabolites involved in the de novo nucleotide synthesis pathway were identified as early prognostic markers that correlated with the initial viral load. We further employed mice models of SARS-CoV2-MA10 and influenza infection to demonstrate that such de-amination of amino acids and de novo synthesis of nucleotides were associated with the abnormal proliferation of airway and vascular tissue cells in the lungs during the early stages of infection. Consequently, it can be concluded that lung parenchymal tissue remodeling in the early stages of respiratory viral infections induces systemic metabolic remodeling and that the associated key amino acid catabolites are valid predictors for excessive inflammatory response in later disease stages.

  • Hydrogen gas and the gut microbiota are potential biomarkers for the development of experimental colitis in mice

    Fujiki Y., Tanaka T., Yakabe K., Seki N., Akiyama M., Uchida K., Kim Y.G.

    Gut Microbiome (Cambridge University Press)  Accepted 2023.11

    Research paper (scientific journal), Joint Work, Last author, Corresponding author, Accepted

  • Dysfunction of Foxp3+ Regulatory T Cells Induces Dysbiosis of Gut Microbiota via Aberrant Binding of Immunoglobulins to Microbes in the Intestinal Lumen

    Koshida K., Ito M., Yakabe K., Takahashi Y., Tai Y., Akasako R., Kimizuka T., Takano S., Sakamoto N., Haniuda K., Ogawa S., Kimura S., Kim Y.G., Hase K., Harada Y.

    Int J Mol Sci. 24 ( 10 ) 8549 2023.05

    Research paper (scientific journal), Accepted

  • Turicibacter and Acidaminococcus predict immune-related adverse events and efficacy of immune checkpoint inhibitor

    Hamada K., Isobe J., Hattori K., Hosonuma M., Baba Y., Murayama M., Narikawa Y., Toyoda H., Funayama E., Tajima K., Shida M., Hirasawa Y., Tsurui T., Ariizumi H., Ishiguro T., Suzuki R., Ohkuma R., Kubota Y., Sambe T., Tsuji M., Wada S., Kiuchi Y., Kobayashi S., Kuramasu A., Horiike A., Kim Y.G., Tsunoda T., Yoshimura K.

    Frontiers in Immunology (Frontiers in Immunology)  14   1164724 2023.04

    Research paper (scientific journal), Joint Work, Accepted

     View Summary

    Introduction: Immune checkpoint inhibitors have had a major impact on cancer treatment. Gut microbiota plays a major role in the cancer microenvironment, affecting treatment response. The gut microbiota is highly individual, and varies with factors, such as age and race. Gut microbiota composition in Japanese cancer patients and the efficacy of immunotherapy remain unknown. Methods: We investigated the gut microbiota of 26 patients with solid tumors prior to immune checkpoint inhibitor monotherapy to identify bacteria involved in the efficacy of these drugs and immune-related adverse events (irAEs). Results: The genera Prevotella and Parabacteroides were relatively common in the group showing efficacy towards the anti-PD-1 antibody treatment (effective group). The proportions of Catenibacterium (P = 0.022) and Turicibacter (P = 0.049) were significantly higher in the effective group than in the ineffective group. In addition, the proportion of Desulfovibrion (P = 0.033) was significantly higher in the ineffective group. Next, they were divided into irAE and non-irAE groups. The proportions of Turicibacter (P = 0.001) and Acidaminococcus (P = 0.001) were significantly higher in the group with irAEs than in those without, while the proportions of Blautia (P = 0.013) and the unclassified Clostridiales (P = 0.027) were significantly higher in the group without irAEs than those with. Furthermore, within the Effective group, Acidaminococcus and Turicibacter (both P = 0.001) were more abundant in the subgroup with irAEs than in those without them. In contrast, Blautia (P = 0.021) and Bilophila (P= 0.033) were statistically significantly more common in those without irAEs. Discussion: Our Study suggests that the analysis of the gut microbiota may provide future predictive markers for the efficacy of cancer immunotherapy or the selection of candidates for fecal transplantation for cancer immunotherapy.

display all >>

Papers, etc., Registered in KOARA 【 Display / hide

Reviews, Commentaries, etc. 【 Display / hide

  • マイクロバイオーム創薬の現状

    金倫基

    MEDCHEM NEWS 33 ( 4 ) 170 - 175 2023.11

    Lead author

  • 腸内細菌の組成や代謝に影響を与えるマイクロバイオームモジュレータ

    佐藤謙介, 金倫基

    生化学 95 ( 4 ) 467 - 474 2023.08

    Article, review, commentary, editorial, etc. (scientific journal), Joint Work, Last author, Corresponding author

  • 腸内細菌代謝物による疾患制御の可能性

    秋山雅博, 金倫基

    臨床免疫・アレルギー科 80 ( 2 ) 180 - 185 2023.08

    Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media), Last author, Corresponding author

  • マイクロバイオーム創薬の現状と課題

    金 倫基

    Trends of Nutrition 栄養 (株式会社ジェフコーポレーション)  38 ( 1 ) 5 - 9 2023.04

    Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media), Lead author, Corresponding author

  • 腸内細菌による肥満制御と実用化の可能性

    内山 純, 金 倫基

    炎症と免疫 30 ( 6 ) 502 - 506 2022.11

    Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media), Corresponding author

display all >>

Presentations 【 Display / hide

  • 腸内環境制御によるサクセスフルエイジングの実現

    金 倫基

    第2回PAC国際シンポジウム, 

    2021.11

    Oral presentation (invited, special), プロダクティブ・エイジング コンソーシアム(PAC)

  • 腸内細菌の創薬応用

    金 倫基

    腸内デザイン学会 腸内環境をデザインする~新たな「腸内細菌叢学」を目指して~, 

    2020.11

    Symposium, workshop panel (nominated)

  • 抗肥満作用を発揮する腸内細菌関連代謝物の探索

    金 倫基

    第20回日本抗加齢医学会総会 腸内細菌の臨床応用 ―便移植からポストバイオティクスまで, 

    2020.09

    Oral presentation (invited, special)

  • 抗肥満作用を発揮する腸内細菌由来代謝物の探索

    金 倫基

    第32回微生物シンポジウム, 

    2020.09

    Symposium, workshop panel (nominated)

  • 腸内細菌と肥満

    金 倫基

    第64回日本薬学会関東支部大会 シンポジウムS5 宿主防御機構の新しい視点, 

    2020.09

    Symposium, workshop panel (nominated)

display all >>

Research Projects of Competitive Funds, etc. 【 Display / hide

  • 生体の体液調節系に腸内細菌叢が与える影響の検証

    2023.06
    -
    2025.03

    挑戦的研究(萌芽), Principal investigator

  • Identification of gut bacteria involved in aggravation of respiratory viral infection

    2023.04
    -
    2026.03

    基盤研究(B), Principal investigator

  • 炎症性腸疾患における腸内細菌病因説の検証

    2020.07
    -
    2022.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Challenging Research (Exploratory), Principal investigator

  • Identification of microbiota-associated metabolite which protects against

    2020.04
    -
    2023.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (B), Principal investigator

  • 腸内細菌叢の成熟に伴う腸管病原菌に対する感染抵抗性獲得機構

    2017.04
    -
    2020.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Young Scientists (A), Principal investigator

 

Courses Taught 【 Display / hide

  • PATHOBIOCHEMISTRY

    2023

  • INTRODUCTION TO THE PHARMACEUTICAL SCIENCES

    2023

  • PATHOBIOCHEMISTRY

    2022

  • INTRODUCTION TO THE PHARMACEUTICAL SCIENCES

    2022

  • PATHOBIOCHEMISTRY

    2021

display all >>